Overview

Evaluating Patients With Varying Degrees of Renal Function

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of renal function. Patients will be stratified by baseline 24-hour creatinine clearance(CrCL) into 4 cohorts using the normal clearance formula: Group A: Control Group B:Mild renal dysfunction Group C:Moderate renal function and Group D: Severe renal dysfunction. Six patients will be enrolled into each cohort.
Phase:
Phase 1
Details
Lead Sponsor:
Taiho Oncology, Inc.
Treatments:
Cisplatin